BlackRock’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $329M | Buy |
15,226,475
+228,584
| +2% | +$4.94M | 0.01% | 1380 |
|
|
2025
Q4 | $357M | Buy |
14,997,891
+3,187,025
| +27% | +$65M | 0.01% | 1320 |
|
|
2025
Q3 | $161M | Buy |
11,810,866
+352,887
| +3% | +$3.67M | ﹤0.01% | 1804 |
|
|
2025
Q2 | $93.3M | Buy |
11,457,979
+590,888
| +5% | +$5.05M | ﹤0.01% | 2096 |
|
|
2025
Q1 | $85.3M | Buy |
10,867,091
+1,172,829
| +12% | +$13.6M | ﹤0.01% | 2097 |
|
|
2024
Q4 | $144M | Sell |
9,694,262
-38,137
| -0.4% | -$623K | ﹤0.01% | 1857 |
|
|
2024
Q3 | $149M | Sell |
9,732,399
-30,714
| -0.3% | -$484K | ﹤0.01% | 1836 |
|
|
2024
Q2 | $149M | Sell |
9,763,113
-137,228
| -1% | -$2.21M | ﹤0.01% | 1794 |
|
|
2024
Q1 | $187M | Sell |
9,900,341
-134,829
| -1% | -$2.33M | ﹤0.01% | 1686 |
|
|
2023
Q4 | $192M | Buy |
10,035,170
+416,343
| +4% | +$6.65M | ﹤0.01% | 1674 |
|
|
2023
Q3 | $173M | Buy |
9,618,827
+146,790
| +2% | +$2.95M | 0.01% | 1633 |
|
|
2023
Q2 | $192M | Sell |
9,472,037
-666,983
| -7% | -$12.7M | 0.01% | 1611 |
|
|
2023
Q1 | $185M | Buy |
10,139,020
+749,972
| +8% | +$14.3M | 0.01% | 1596 |
|
|
2022
Q4 | $194M | Buy |
9,389,048
+460,820
| +5% | +$12.7M | 0.01% | 1549 |
|
|
2022
Q3 | $234M | Buy |
8,928,228
+805,534
| +10% | +$21.3M | 0.01% | 1353 |
|
|
2022
Q2 | $206M | Buy |
8,122,694
+3,983,168
| +96% | +$97.5M | 0.01% | 1510 |
|
|
2022
Q1 | $131M | Buy |
4,139,526
+9,597
| +0.2% | +$322K | ﹤0.01% | 1957 |
|
|
2021
Q4 | $167M | Sell |
4,129,929
-73,031
| -2% | -$2.83M | ﹤0.01% | 1874 |
|
|
2021
Q3 | $147M | Buy |
4,202,960
+164,232
| +4% | +$5.11M | ﹤0.01% | 1947 |
|
|
2021
Q2 | $111M | Buy |
4,038,728
+645,082
| +19% | +$18.4M | ﹤0.01% | 2183 |
|
|
2021
Q1 | $95.3M | Buy |
3,393,646
+138,555
| +4% | +$4.82M | ﹤0.01% | 2220 |
|
|
2020
Q4 | $84.5M | Buy |
3,255,091
+125,809
| +4% | +$3.05M | ﹤0.01% | 2175 |
|
|
2020
Q3 | $53.6M | Buy |
3,129,282
+490,190
| +19% | +$11M | ﹤0.01% | 2257 |
|
|
2020
Q2 | $65.3M | Sell |
2,639,092
-141,256
| -5% | -$3.81M | ﹤0.01% | 2104 |
|
|
2020
Q1 | $38.6M | Sell |
2,780,348
-228,414
| -8% | -$2.84M | ﹤0.01% | 2221 |
|
|
2019
Q4 | $30.4M | Buy |
3,008,762
+106,774
| +4% | +$898K | ﹤0.01% | 2648 |
|
|
2019
Q3 | $26.4M | Buy |
2,901,988
+665,855
| +30% | +$5.35M | ﹤0.01% | 2659 |
|
|
2019
Q2 | $17.8M | Buy |
2,236,133
+404,432
| +22% | +$4.05M | ﹤0.01% | 2913 |
|
|
2019
Q1 | $22.9M | Buy |
1,831,701
+109,807
| +6% | +$1.19M | ﹤0.01% | 2679 |
|
|
2018
Q4 | $18.5M | Buy |
1,721,894
+1,286,470
| +295% | +$15M | ﹤0.01% | 2755 |
|
|
2018
Q3 | $6.07M | Buy |
435,424
+100,154
| +30% | +$1.28M | ﹤0.01% | 3443 |
|
|
2018
Q2 | $4.1M | Buy |
335,270
+315,621
| +1,606% | +$4.95M | ﹤0.01% | 3546 |
|
|
2018
Q1 | $303K | Buy |
+19,649
| New | +$327K | ﹤0.01% | 4127 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
BlackRock's RCUS Position: Q1 2026 in Review
BlackRock increased its Arcus Biosciences (RCUS) stake by 1.5% in Q1 2026, buying an estimated $4.94M and bringing the position to 15,226,475 shares worth $329M. The position accounts for 0.01% of the portfolio, ranked #1380.
BlackRock first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $357M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- BlackRock held 15,226,475 shares of Arcus Biosciences worth $329M as of Q1 2026.
- BlackRock bought 228,584 Arcus Biosciences shares in Q1 2026, an estimated $4.94M.
- Arcus Biosciences made up 0.01% of BlackRock's portfolio in Q1 2026, its #1380 holding.
- BlackRock first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
- BlackRock's Arcus Biosciences position peaked at $357M in Q4 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.